[1]
|
S. Melmed, “Acromegaly Pathogenesis and Treatment,” 2009. http://www.ncbi.nlm.nih.gov/pubmed/19884662
|
[2]
|
S. Melmed, “Medical Progress: Acromegaly,” 2006.
http://www.ncbi.nlm.nih.gov/pubmed/17167139
|
[3]
|
B. A. Bengtsson, S. Eden, I. Ernest, A. Odén and B. Sj?gren, “Epidemiology and Long-Term Survival in Acromegaly: A Study of 166 Cases Diagnosed between 1955 and 1984,” 1988.
http://www.ncbi.nlm.nih.gov/pubmed/3369313
|
[4]
|
S. Melmed, A. Colao, A. Barkan, M. Molitch, A. B. Grossman and D. Kleinberg, “Guidelines for Acromegaly Management: An Update,” 2009.
http://www.ncbi.nlm.nih.gov/pubmed/19208732
|
[5]
|
A. Colao, D. Ferone, P. Marzullo and G. Lombardi, “Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management,” 2004.
http://www.ncbi.nlm.nih.gov/pubmed/14769829
|
[6]
|
O. Dekkers, N. Biermasz, A. Pereira, J. Romijn, J. Vandenbroucke, “Mortality in acromegaly: A metaanalysis,” 2008.
http://www.ncbi.nlm.nih.gov/pubmed/17971431
|
[7]
|
A. Barkan, M. D. Bronstein, O. D. Bruno, A. Cob, A. L. Espinosa de los Monteros and M. R. Gadelha, “Management of Acromegaly in Latin America: Expert Panel Recommendations,” 2010.
http://www.ncbi.nlm.nih.gov/pubmed?term=Management%20of%20acromegaly%20in%20latin%20america%3A%20Expert%20panel%20recommendations
|
[8]
|
E. R. Laws, “Surgery for Acromegaly: Evolution of the Techniques and Outcomes,” 2008.
http://www.ncbi.nlm.nih.gov/pubmed/18228147
|
[9]
|
R. Cozzi, M. Montini, R. Attanasio, M. Albizzi, G. Lasio and S. Lodrini, “Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor Shrinkage,” 2006.
http://www.ncbi.nlm.nih.gov/pubmed/16449332
|
[10]
|
R. D. Murray and S. Melmed, “A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly,” 2008.
http://www.ncbi.nlm.nih.gov/pubmed/18477663 doi:10.1210/jc.2008-0027
|
[11]
|
U. P. Freda, C. M. Reyes, A. T. Nuruzzaman, R. E. Sundeen, A. G. Khandji and K. D. Post, “Cabergoline Therapy of Growth Hormone & Growth Hormone/Prolactin Secreting Pituitary Tumors,” 2004.
http://www.ncbi.nlm.nih.gov/pubmed/15638294
|
[12]
|
P. J. Jenkins, P. Bates, M. N. Carson, P. M. Stewart and J. A. Wass, “Conventional Pituitary Irradiation Is Effective in Lowering Serum Growth Hormone and Insulin-Like Growth Factor-I in Patients with Acromegaly,” 2006.
http://www.ncbi.nlm.nih.gov/pubmed/16403824
|
[13]
|
R. D. Murray and S. Melmed, “A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly,” 2008.
http://www.ncbi.nlm.nih.gov/pubmed/18477663
doi:10.1210/jc.2008-0027
|
[14]
|
R. Cozzi, R. Attanasio, S. Lodrini and G. Lasio, “Cabergoline Addition to Depot Somatostatin Analogues in Resistant Acromegalic Patients: Efficacy and Lack of Predictive Value of Prolactin Status,” 2004.
http://www.ncbi.nlm.nih.gov/pubmed/15272916
|
[15]
|
Tabla Anual de Mortalidad, “DANE—Departamento Dministrative Nacional de Estadistica,” 2010.
http://www.dane.gov.co/daneweb_V09/
|
[16]
|
J. Valentim, V. Passos, F. Mataveli and A. Calabró, “Cost-Effectiveness Analysis of Somatostatin Analogues in the Treatment of Acromegaly in Brazil” 2008.
http://www.ncbi.nlm.nih.gov/pubmed/19197453
|
[17]
|
P. Chanson, “Predicting the Effects of Long-Term Medical Treatment in Acromegaly at What Cost? For What Benefits?” 1997.
http://www.ncbi.nlm.nih.gov/pubmed/9150692
|
[18]
|
D. Moore, C. Meads, L. Roberts, F. Song and E. Date, “The Effectiveness and Cost-Effectiveness of Somatostatin Analogues in the Treatment of Acromegaly,” 2002. http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=32002000871
|